Award of Innovative Technology Contract for Helicoll
Helicoll biological skin substitute product has received an Innovative Technology contract from Vizient, Inc., the largest member-driven healthcare performance…
Helicoll® is a bioengineered high purity Type-I collagen (>97% pure) forming an acellular skin substitute construct that is highly bioactive, cell conducive, and supportive towards enhancing tissue generation for wound management. Helicoll® is an acellular dermal replacement product and is within the definition of a bioengineered skin substitute. It provides a framework that promotes the regeneration of blood vessels and supports biologic cell migration due to the resorbable properties of Helicoll®. Treatment course typically involves 1 to 4 applications.
EnColl Corporation, established in 1994, is a California corporation that develops, manufactures and markets Type-I collagen-based products. EnColl uses its patented technology for the preparation of high purity and charge modified collagen (U.S. Patents 5,814,328 (1998); 6,127,143 (2000) & 6,548,077(2003).
The company’s technologies and manufacturing system yields a series of high quality products required for various medical fields such as general and plastic surgery (healing of wounds, burns and dermal ulcers/sores), orthopedic surgery (bone regeneration, spinal fusion), oral surgery (periodontal and dental products), and neurological injuries (brain/nerve regeneration), drug delivery, biopharmaceutical research, and cosmetic & dietary applications.
Helicoll biological skin substitute product has received an Innovative Technology contract from Vizient, Inc., the largest member-driven healthcare performance…
EnColl offers the only manufacturing process which produces high purity, surgical grade collagen with EnColl’s patented Phosphorylated modifications to the Ultra-pure collagen substratum…
The purpose of this study is to confirm Helicoll’s clinical effectiveness in promoting EB wound healing and reducing patient pain…